Propel(x) Portfolio Company Trailhead Biosystems Launches Innovative iPSC-Derived Hematopoietic Progenitor Cells.
We’re thrilled to announce Propel(x) portfolio company Trailhead Biosystems: the release of their latest product, TrailBio® iPSC-derived Hematopoietic Progenitor Cells (HPCs). This launch marks a major milestone, showcasing Trailhead’s commitment to advancing cell-based research and therapies.
Trailhead’s Mesoderm Team, led by Angelica M. Gomes Ueltschy, PhD, developed TrailBio® HPCs. They used a novel High-Dimensional Design of Experiments (HD-DoE) approach to create an efficient and reproducible process. This method enables the robust induction of hemogenic endothelium and the generation of homogeneous early-stage hematopoietic progenitor cells.
Key features of TrailBio® HPCs include:
– Validated for key markers: Ensuring quality and consistency with validation for CD34, CD43, and CD90.
– Ready-to-use: Designed for immediate integration into your research workflows.
– Designed for reproducibility: Delivering consistent results across different lots.
– Multipotent potential: Offering the ability for customized downstream differentiation into various blood lineages.
These versatile cells are ideal for a range of critical applications, including disease modeling, drug discovery, and toxicology studies.
About Trailhead Biosystems
Trailhead Biosystems leverages machine learning, bioinformatics, and automation to produce high-quality human cells. Their proprietary HD-DoE platform ensures superior purity, reproducibility, and cost-effectiveness, supplying specialized cells to global biopharma and research organizations.
At Propelx, we are incredibly proud to have supported Trailhead Biosystems through an SPV on our platform. We eagerly anticipate their continued progress and impact on the scientific community.
Register on Propelx to invest in the future of innovation
https://www.propelx.com/
